Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
Seftika Sari1,2, Tri Murti Andayani3*, Dwi Endarti4, Kartika Widayati5
1Doctoral Program in Pharmaceutical Science, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
2Sekolah Tinggi Ilmu Farmasi Riau, Pekanbaru, Indonesia
3Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia
4Department of Pharmaceutics, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia
5Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Gadjah Mada University-Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Volume - 13,
Issue - 1,
Year - 2020
Background: Aside from being the main goal for therapy, Health-Related Quality of Life (HRQOL) also can also be used for pharmacoeconomic analysis or Health Technology Assessment (HTA). The Study on HRQOL employing the EQ-5D-5L questionnaire was still limited. It aims to calculate the HRQOL according to health status and to know the determinant factors which affect the NSCLC mutation EGFR patients' quality of life.
Methods and Material: A cross-sectional study was performed by interviewing with the patients using EQ 5D 5L questionnaire in RSUP Dr. Sardjito, Yogyakarta and RSUP Dr. Kariadi, Semarang, Indonesia
Patients’ health status was consisted of Progression Free / PF (no progression), Progressive Disease 1 / PD1 (experiencing progression before or when diagnosed NSCLC with mutation of EGFR), and Progressive Disease2/PD2 (experiencing progression after being diagnosed NCLC with mutation of EGFR)
Result: There were 74 patients identified, 29 patients had not experienced disease progression (PF), 21 patients experienced the progress before or altogether after being diagnosed with NSCLC EGFR mutation positive (PD1), and 24 patients experienced the progression of the disease after being diagnosed with NSCLC EGFR mutation positive (PD2). Common problems occurred such as pain and usual activities (75,7% and 60,8%.). The mean of the utility value (SD) on patients PF, PD1, and PD2 were 0,824 (0,164); 0,528 (0,489); 0,544 (0,339). The mean of EQ5D VAS on PF, PD1, and PD2 patients were 69,65 (9,904); 57,14 (16,09); 53,95 (11,12). Mann Whitney test and Kruskal-Wallis test showed that age, gender, and mutation type did not affect the patients' utility, yet according to descriptive statistic and Kruskal-Wallis test, it was shown that health status affects patients' HRQOL.
Conclusion: NSCL EGFR mutation brought negative impact on patients' HRQOL and patients' health status significantly affected HRQOL in NSCLC EGFR mutation-positive patients.
Cite this article:
Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati. Health-Related Quality of Life in Non-Small Cell Lung Cancer (NSCLC) Patients with Mutation of Epidermal Growth Factor Receptor (EGFR) in Indonesia. Research J. Pharm. and Tech. 2020; 13(1):443-447. doi: 10.5958/0974-360X.2020.00086.4
Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati. Health-Related Quality of Life in Non-Small Cell Lung Cancer (NSCLC) Patients with Mutation of Epidermal Growth Factor Receptor (EGFR) in Indonesia. Research J. Pharm. and Tech. 2020; 13(1):443-447. doi: 10.5958/0974-360X.2020.00086.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-1-86